MNOV

MediciNova

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Strong Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About MNOV

Medicinova, Inc.

A biopharmaceutical company developing products primarily focused on neurology, respiratory

Industry

Biological Technology

Established Date

09/26/2000

Listing Date

12/07/2006

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.medicinova.com

Security Type

Common stock

Office address

4275 Executive Square , Suite 300 , La Jolla , CA 92037

Business

Introduction

MediciNova, Inc., was incorporated in Delaware on September 26, 2000. In December 2009, it acquired a biopharmaceutical company called Avigen Inc., which focuses on finding and developing differentiated products to treat patients with severe disorders. The company's product candidates are for inhibiting cell movement and glial attenuators in the macrophage central nervous system, such as neuropathic pain, opioid addiction and withdrawal, and physical disorders such as methamphetamine addiction. MediciNova, Inc., is a developing biopharmaceutical company focused on acquiring and developing novel small molecule therapies to treat serious and specific diseases with unmet medical needs in the US market. Through strategic alliances, mainly with Japanese pharmaceutical companies, the company has an ownership interest in a diverse range of clinical and preclinical product candidates and believes that this will provide the company with significant business opportunities.

Company Financials

EPS

MNOV has released its 2024 Q4 earnings. EPS was reported at -0.06, versus the expected -0.05, missing expectations. The chart below visualizes how MNOV has performed over recent quarters, highlighting trends in earnings surprises.